Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10471044rdf:typepubmed:Citationlld:pubmed
pubmed-article:10471044lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:10471044lifeskim:mentionsumls-concept:C0220655lld:lifeskim
pubmed-article:10471044pubmed:issue12lld:pubmed
pubmed-article:10471044pubmed:dateCreated1999-9-21lld:pubmed
pubmed-article:10471044pubmed:abstractTextMalignant pericardial effusion is usually treated only when signs of cardiac tamponade develop. Several methods of treatment have been reported with an overall response rate of approximately 75%. Since our initial study using intrapericardial 32P-colloid instillation as a treatment modality for pericardial effusion demonstrated a significant higher response rate, this study was conducted to further evaluate the efficacy of intrapericardial 32P-colloid in terms of response rates and duration of remissions. Intrapericardial instillation of 185-370 MBq (5-10 mCi) 32P-colloid in 36 patients with malignant pericardial effusion resulted in a complete remission rate of 94.5% (34 patients) whereas two patients did not respond to treatment due to a foudroyant formation of pericardial fluid. The median duration time was 8 months. No side-effects were observed. These results suggest that intrapericardial instillation of 32P-colloid is a simple, reliable and safe treatment strategy for patients with malignant pericardial effusions. Therefore, since further evidence is provided that 32P-colloid is significantly more effective than external radiation or non-radioactive sclerosing agents, this treatment modality should be considered for the management of malignant pericardial effusion.lld:pubmed
pubmed-article:10471044pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:languageenglld:pubmed
pubmed-article:10471044pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:citationSubsetIMlld:pubmed
pubmed-article:10471044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10471044pubmed:statusMEDLINElld:pubmed
pubmed-article:10471044pubmed:monthAuglld:pubmed
pubmed-article:10471044pubmed:issn0007-0920lld:pubmed
pubmed-article:10471044pubmed:authorpubmed-author:FirusianNNlld:pubmed
pubmed-article:10471044pubmed:authorpubmed-author:DempkeWWlld:pubmed
pubmed-article:10471044pubmed:issnTypePrintlld:pubmed
pubmed-article:10471044pubmed:volume80lld:pubmed
pubmed-article:10471044pubmed:ownerNLMlld:pubmed
pubmed-article:10471044pubmed:authorsCompleteYlld:pubmed
pubmed-article:10471044pubmed:pagination1955-7lld:pubmed
pubmed-article:10471044pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:10471044pubmed:meshHeadingpubmed-meshheading:10471044...lld:pubmed
pubmed-article:10471044pubmed:meshHeadingpubmed-meshheading:10471044...lld:pubmed
pubmed-article:10471044pubmed:meshHeadingpubmed-meshheading:10471044...lld:pubmed
pubmed-article:10471044pubmed:meshHeadingpubmed-meshheading:10471044...lld:pubmed
pubmed-article:10471044pubmed:meshHeadingpubmed-meshheading:10471044...lld:pubmed
pubmed-article:10471044pubmed:meshHeadingpubmed-meshheading:10471044...lld:pubmed
pubmed-article:10471044pubmed:meshHeadingpubmed-meshheading:10471044...lld:pubmed
pubmed-article:10471044pubmed:meshHeadingpubmed-meshheading:10471044...lld:pubmed
pubmed-article:10471044pubmed:meshHeadingpubmed-meshheading:10471044...lld:pubmed
pubmed-article:10471044pubmed:meshHeadingpubmed-meshheading:10471044...lld:pubmed
pubmed-article:10471044pubmed:meshHeadingpubmed-meshheading:10471044...lld:pubmed
pubmed-article:10471044pubmed:meshHeadingpubmed-meshheading:10471044...lld:pubmed
pubmed-article:10471044pubmed:meshHeadingpubmed-meshheading:10471044...lld:pubmed
pubmed-article:10471044pubmed:year1999lld:pubmed
pubmed-article:10471044pubmed:articleTitleTreatment of malignant pericardial effusion with 32P-colloid.lld:pubmed
pubmed-article:10471044pubmed:affiliationMartin-Luther-University Halle-Wittenberg, Department of Internal Medicine IV, Halle, Germany.lld:pubmed
pubmed-article:10471044pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10471044pubmed:publicationTypeClinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10471044lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10471044lld:pubmed